TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
Open Access
- 2 April 2007
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (4) , 812-817
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from AntiplasminJournal of Biological Chemistry, 2004
- Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2003
- Structural/Functional Characterization of the α2-Plasmin Inhibitor C-Terminal PeptideBiochemistry, 2003
- A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin ComplexJournal of Biological Chemistry, 1996
- Plasma carboxypeptidases as regulators of the plasminogen system.Journal of Clinical Investigation, 1995
- Activation and Characterization of Procarboxypeptidase B from Human PlasmaBiochemistry, 1995
- Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.Journal of Clinical Investigation, 1993
- Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysinesBiochemistry, 1991
- Plasminogen activator inhibitor (PAI‐1) in plasma and plateletsBritish Journal of Haematology, 1988